TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Pre-clinical studies have shown that TP53 mutations can account for acquired resistance to HDM2 antagonists. This study provides clinical evidence for the emergence of TP53mutations in circulating cell-free DNA, seen in 5 out of 20 de-differentiated liposarcoma patients treated with an HDM2 antagoni...

Full description

Bibliographic Details
Main Authors: Joonil Jung, Joon Sang Lee, Mark A. Dickson, Gary K. Schwartz, Axel Le Cesne, Andrea Varga, Rastilav Bahleda, Andrew J. Wagner, Edwin Choy, Maja J. de Jonge, Madelyn Light, Steve Rowley, Sandrine Macé, James Watters
Format: Article
Language:English
Published: Nature Portfolio 2016-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms12609

Similar Items

Similar Items